The company announced the results on Saturday, 12 May 2012.

Meanwhile, the BSE Sensex was up 63.37 points or 0.39% to 16,356.35.

On BSE, 38,000 shares were traded in the counter as against average daily volume of 17,179 shares over the past one quarter.

The stock hit a high of Rs 867.90 and a low of Rs 850 so far during the day. The stock had hit a 52-week high of Rs 877.95 on 2 May 2012. The stock had hit a 52-week low of Rs 690 on 26 August 2011.

The large-cap stock had outperformed the market over the past one month till 11 May 2012, rising 6.32% compared with the Sensex's 5.27% fall. The scrip had also outperformed the market in past one quarter, surging 8.99% as against Sensex's 8.2% fall.

The company has an equity capital of Rs 26.55 crore. Face value per share is Rs 2.

Divi's Laboratories' consolidated net profit rose 24% to Rs 533 crore on 41.53% growth in total income to Rs 1864 crore in the year ended 31 March 2012 over the year ended 31 March 2011.

Tax expense for FY 2012 was Rs 147 crore, as against Rs 43 crore in FY 2011. Higher tax provision in FY 2012 was due to the regular tax provisions for the export oriented unit (EoU) and exemption at the rate of 50% of export profits for the first SEZ unit, Divi's Laboratories' said in a statement.

Divi's Laboratories said the business has grown satisfactorily across all segments. Exports constituted 89% of sales and about 71% to advanced markets in North America and Europe, the company added.

During the year, the DSN SEZ facility at Visakhapatnam has commenced commercial operations. This facility as well as the additional capacities created at the existing facilities has contributed to business growth during the year, Divi's Laboratories' said in a statement.

Divi's Laboratories' board of directors at a meeting held on Saturday, 12 May 2012, recommended a dividend of Rs 13 per share for the year ended March 2012.

Divi's Laboratories product portfolio comprises generic active pharmaceutical ingredients (APIs) and custom synthesis of APIs, intermediates and specialty ingredients for innovator pharma giants. Custom synthesis also includes peptide building blocks (protected amino acids).